Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort
Identifieur interne : 002589 ( Main/Merge ); précédent : 002588; suivant : 002590Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort
Auteurs : P. Damier [France] ; F. Viallet [France] ; M. Ziegler [France] ; I. Bourdeix [France] ; K. Rerat [France]Source :
- European Journal of Neurology [ 1351-5101 ] ; 2008-07.
Descripteurs français
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- Activities of Daily Living, Aged, Antiparkinson Agents (administration & dosage), Catechols (administration & dosage), Dopa Decarboxylase (administration & dosage), Drug Therapy, Combination, Dyskinesia, Drug-Induced (prevention & control), Enzyme Inhibitors (administration & dosage), Female, France, Humans, Levodopa (administration & dosage), Male, Middle Aged, Nitriles (administration & dosage), Parkinson Disease (drug therapy), Practice Patterns, Physicians', Retrospective Studies, activities of daily living, entacapone, levodopa, motor fluctuations.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Catechols, Dopa Decarboxylase, Enzyme Inhibitors, Levodopa, Nitriles.
- geographic : France.
- drug therapy : Parkinson Disease.
- prevention & control : Dyskinesia, Drug-Induced.
- Activities of Daily Living, Aged, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Practice Patterns, Physicians', Retrospective Studies.
Abstract
Levodopa is the gold standard drug for the symptomatic control of Parkinson’s disease (PD). However, long‐term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re‐emergence of symptoms because of wearing‐off and dyskinesia. Treatment with levodopa/DDCI and entacapone extends the half‐life of levodopa, avoiding deep troughs in levodopa plasma levels and providing more continuous delivery of levodopa to the brain. In this open‐label, retrospective, observational study we investigated the effects of levodopa/DDCI and entacapone therapy in 800 PD patients with motor fluctuations. Levodopa/DDCI and entacapone treatment was assessed as good/very good in improving motor fluctuations (64%) and activities of daily living (ADL; 62%). The therapeutic utility was considered to be good/very good in 70% of cases. Moreover, there was a reduction in levodopa dose in 20% of patients. Neurologists preferred levodopa/DDCI and entacapone compared with increasing levodopa dosage, dose‐fractionation or addition of a dopamine agonist (63%, 29% and 23% of patients respectively). Reasons included achieving more continuous dopaminergic stimulation (40%), reducing motor fluctuations (54%) and improving ADL (41%). This analysis reveals the preference of neurologists for levodopa/DDCI and entacapone over conventional levodopa‐modification strategies for the effective treatment of PD motor fluctuations in clinical practice.
Url:
DOI: 10.1111/j.1468-1331.2008.02165.x
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000C74
- to stream Istex, to step Curation: 000C72
- to stream Istex, to step Checkpoint: 000785
- to stream PubMed, to step Corpus: 000C81
- to stream PubMed, to step Curation: 000C41
- to stream PubMed, to step Checkpoint: 000C41
- to stream Ncbi, to step Merge: 000874
- to stream Ncbi, to step Curation: 000874
- to stream Ncbi, to step Checkpoint: 000874
Links to Exploration step
ISTEX:FB1AF7A778E8460826C64B435617CFBBC987FCD1Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort</title>
<author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P." last="Damier">P. Damier</name>
</author>
<author><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F." last="Viallet">F. Viallet</name>
</author>
<author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M." last="Ziegler">M. Ziegler</name>
</author>
<author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I." last="Bourdeix">I. Bourdeix</name>
</author>
<author><name sortKey="Rerat, K" sort="Rerat, K" uniqKey="Rerat K" first="K." last="Rerat">K. Rerat</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:FB1AF7A778E8460826C64B435617CFBBC987FCD1</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1111/j.1468-1331.2008.02165.x</idno>
<idno type="url">https://api.istex.fr/document/FB1AF7A778E8460826C64B435617CFBBC987FCD1/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000C74</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C74</idno>
<idno type="wicri:Area/Istex/Curation">000C72</idno>
<idno type="wicri:Area/Istex/Checkpoint">000785</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000785</idno>
<idno type="wicri:doubleKey">1351-5101:2008:Damier P:levodopa:ddci:and</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:18582341</idno>
<idno type="wicri:Area/PubMed/Corpus">000C81</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C81</idno>
<idno type="wicri:Area/PubMed/Curation">000C41</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C41</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000C41</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C41</idno>
<idno type="wicri:Area/Ncbi/Merge">000874</idno>
<idno type="wicri:Area/Ncbi/Curation">000874</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000874</idno>
<idno type="wicri:Area/Main/Merge">002589</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort</title>
<author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P." last="Damier">P. Damier</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes</wicri:regionArea>
<placeName><region type="region">Pays de la Loire</region>
<region type="old region">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F." last="Viallet">F. Viallet</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Service de Neurologie, CH du Pays d’Aix, Aix en Provence</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Aix-en-Provence</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M." last="Ziegler">M. Ziegler</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Hopital Léopold Belan, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I." last="Bourdeix">I. Bourdeix</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex</wicri:regionArea>
<wicri:noRegion>Rueil‐Malmaison Cedex</wicri:noRegion>
<wicri:noRegion>Rueil‐Malmaison Cedex</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rerat, K" sort="Rerat, K" uniqKey="Rerat K" first="K." last="Rerat">K. Rerat</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex</wicri:regionArea>
<wicri:noRegion>Rueil‐Malmaison Cedex</wicri:noRegion>
<wicri:noRegion>Rueil‐Malmaison Cedex</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">European Journal of Neurology</title>
<idno type="ISSN">1351-5101</idno>
<idno type="eISSN">1468-1331</idno>
<imprint><publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2008-07">2008-07</date>
<biblScope unit="volume">15</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="643">643</biblScope>
<biblScope unit="page" to="648">648</biblScope>
</imprint>
<idno type="ISSN">1351-5101</idno>
</series>
<idno type="istex">FB1AF7A778E8460826C64B435617CFBBC987FCD1</idno>
<idno type="DOI">10.1111/j.1468-1331.2008.02165.x</idno>
<idno type="ArticleID">ENE2165</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1351-5101</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Catechols (administration & dosage)</term>
<term>Dopa Decarboxylase (administration & dosage)</term>
<term>Drug Therapy, Combination</term>
<term>Dyskinesia, Drug-Induced (prevention & control)</term>
<term>Enzyme Inhibitors (administration & dosage)</term>
<term>Female</term>
<term>France</term>
<term>Humans</term>
<term>Levodopa (administration & dosage)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nitriles (administration & dosage)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Practice Patterns, Physicians'</term>
<term>Retrospective Studies</term>
<term>activities of daily living</term>
<term>entacapone</term>
<term>levodopa</term>
<term>motor fluctuations</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Catechols</term>
<term>Dopa Decarboxylase</term>
<term>Enzyme Inhibitors</term>
<term>Levodopa</term>
<term>Nitriles</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Practice Patterns, Physicians'</term>
<term>Retrospective Studies</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa is the gold standard drug for the symptomatic control of Parkinson’s disease (PD). However, long‐term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re‐emergence of symptoms because of wearing‐off and dyskinesia. Treatment with levodopa/DDCI and entacapone extends the half‐life of levodopa, avoiding deep troughs in levodopa plasma levels and providing more continuous delivery of levodopa to the brain. In this open‐label, retrospective, observational study we investigated the effects of levodopa/DDCI and entacapone therapy in 800 PD patients with motor fluctuations. Levodopa/DDCI and entacapone treatment was assessed as good/very good in improving motor fluctuations (64%) and activities of daily living (ADL; 62%). The therapeutic utility was considered to be good/very good in 70% of cases. Moreover, there was a reduction in levodopa dose in 20% of patients. Neurologists preferred levodopa/DDCI and entacapone compared with increasing levodopa dosage, dose‐fractionation or addition of a dopamine agonist (63%, 29% and 23% of patients respectively). Reasons included achieving more continuous dopaminergic stimulation (40%), reducing motor fluctuations (54%) and improving ADL (41%). This analysis reveals the preference of neurologists for levodopa/DDCI and entacapone over conventional levodopa‐modification strategies for the effective treatment of PD motor fluctuations in clinical practice.</div>
</front>
</TEI>
<double doi="10.1111/j.1468-1331.2008.02165.x"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort</title>
<author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P." last="Damier">P. Damier</name>
</author>
<author><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F." last="Viallet">F. Viallet</name>
</author>
<author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M." last="Ziegler">M. Ziegler</name>
</author>
<author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I." last="Bourdeix">I. Bourdeix</name>
</author>
<author><name sortKey="Rerat, K" sort="Rerat, K" uniqKey="Rerat K" first="K." last="Rerat">K. Rerat</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:FB1AF7A778E8460826C64B435617CFBBC987FCD1</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1111/j.1468-1331.2008.02165.x</idno>
<idno type="url">https://api.istex.fr/document/FB1AF7A778E8460826C64B435617CFBBC987FCD1/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000C74</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C74</idno>
<idno type="wicri:Area/Istex/Curation">000C72</idno>
<idno type="wicri:Area/Istex/Checkpoint">000785</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000785</idno>
<idno type="wicri:doubleKey">1351-5101:2008:Damier P:levodopa:ddci:and</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort</title>
<author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P." last="Damier">P. Damier</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes</wicri:regionArea>
<placeName><region type="region">Pays de la Loire</region>
<region type="old region">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F." last="Viallet">F. Viallet</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Service de Neurologie, CH du Pays d’Aix, Aix en Provence</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Aix-en-Provence</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M." last="Ziegler">M. Ziegler</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Hopital Léopold Belan, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I." last="Bourdeix">I. Bourdeix</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex</wicri:regionArea>
<wicri:noRegion>Rueil‐Malmaison Cedex</wicri:noRegion>
<wicri:noRegion>Rueil‐Malmaison Cedex</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rerat, K" sort="Rerat, K" uniqKey="Rerat K" first="K." last="Rerat">K. Rerat</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex</wicri:regionArea>
<wicri:noRegion>Rueil‐Malmaison Cedex</wicri:noRegion>
<wicri:noRegion>Rueil‐Malmaison Cedex</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">European Journal of Neurology</title>
<idno type="ISSN">1351-5101</idno>
<idno type="eISSN">1468-1331</idno>
<imprint><publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2008-07">2008-07</date>
<biblScope unit="volume">15</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="643">643</biblScope>
<biblScope unit="page" to="648">648</biblScope>
</imprint>
<idno type="ISSN">1351-5101</idno>
</series>
<idno type="istex">FB1AF7A778E8460826C64B435617CFBBC987FCD1</idno>
<idno type="DOI">10.1111/j.1468-1331.2008.02165.x</idno>
<idno type="ArticleID">ENE2165</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1351-5101</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>activities of daily living</term>
<term>entacapone</term>
<term>levodopa</term>
<term>motor fluctuations</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa is the gold standard drug for the symptomatic control of Parkinson’s disease (PD). However, long‐term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re‐emergence of symptoms because of wearing‐off and dyskinesia. Treatment with levodopa/DDCI and entacapone extends the half‐life of levodopa, avoiding deep troughs in levodopa plasma levels and providing more continuous delivery of levodopa to the brain. In this open‐label, retrospective, observational study we investigated the effects of levodopa/DDCI and entacapone therapy in 800 PD patients with motor fluctuations. Levodopa/DDCI and entacapone treatment was assessed as good/very good in improving motor fluctuations (64%) and activities of daily living (ADL; 62%). The therapeutic utility was considered to be good/very good in 70% of cases. Moreover, there was a reduction in levodopa dose in 20% of patients. Neurologists preferred levodopa/DDCI and entacapone compared with increasing levodopa dosage, dose‐fractionation or addition of a dopamine agonist (63%, 29% and 23% of patients respectively). Reasons included achieving more continuous dopaminergic stimulation (40%), reducing motor fluctuations (54%) and improving ADL (41%). This analysis reveals the preference of neurologists for levodopa/DDCI and entacapone over conventional levodopa‐modification strategies for the effective treatment of PD motor fluctuations in clinical practice.</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.</title>
<author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name>
<affiliation wicri:level="3"><nlm:affiliation>INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes, France. philippe.damier@chu-nantes.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes</wicri:regionArea>
<placeName><region type="region">Pays de la Loire</region>
<region type="old region">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F" last="Viallet">F. Viallet</name>
</author>
<author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M" last="Ziegler">M. Ziegler</name>
</author>
<author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I" last="Bourdeix">I. Bourdeix</name>
</author>
<author><name sortKey="Rerat, K" sort="Rerat, K" uniqKey="Rerat K" first="K" last="Rerat">K. Rerat</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18582341</idno>
<idno type="pmid">18582341</idno>
<idno type="doi">10.1111/j.1468-1331.2008.02165.x</idno>
<idno type="wicri:Area/PubMed/Corpus">000C81</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C81</idno>
<idno type="wicri:Area/PubMed/Curation">000C41</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C41</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000C41</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C41</idno>
<idno type="wicri:Area/Ncbi/Merge">000874</idno>
<idno type="wicri:Area/Ncbi/Curation">000874</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000874</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.</title>
<author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name>
<affiliation wicri:level="3"><nlm:affiliation>INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes, France. philippe.damier@chu-nantes.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes</wicri:regionArea>
<placeName><region type="region">Pays de la Loire</region>
<region type="old region">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F" last="Viallet">F. Viallet</name>
</author>
<author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M" last="Ziegler">M. Ziegler</name>
</author>
<author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I" last="Bourdeix">I. Bourdeix</name>
</author>
<author><name sortKey="Rerat, K" sort="Rerat, K" uniqKey="Rerat K" first="K" last="Rerat">K. Rerat</name>
</author>
</analytic>
<series><title level="j">European journal of neurology</title>
<idno type="eISSN">1468-1331</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Catechols (administration & dosage)</term>
<term>Dopa Decarboxylase (administration & dosage)</term>
<term>Drug Therapy, Combination</term>
<term>Dyskinesia, Drug-Induced (prevention & control)</term>
<term>Enzyme Inhibitors (administration & dosage)</term>
<term>Female</term>
<term>France</term>
<term>Humans</term>
<term>Levodopa (administration & dosage)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nitriles (administration & dosage)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Practice Patterns, Physicians'</term>
<term>Retrospective Studies</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Catechols</term>
<term>Dopa Decarboxylase</term>
<term>Enzyme Inhibitors</term>
<term>Levodopa</term>
<term>Nitriles</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Practice Patterns, Physicians'</term>
<term>Retrospective Studies</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa is the gold standard drug for the symptomatic control of Parkinson's disease (PD). However, long-term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re-emergence of symptoms because of wearing-off and dyskinesia. Treatment with levodopa/DDCI and entacapone extends the half-life of levodopa, avoiding deep troughs in levodopa plasma levels and providing more continuous delivery of levodopa to the brain. In this open-label, retrospective, observational study we investigated the effects of levodopa/DDCI and entacapone therapy in 800 PD patients with motor fluctuations. Levodopa/DDCI and entacapone treatment was assessed as good/very good in improving motor fluctuations (64%) and activities of daily living (ADL; 62%). The therapeutic utility was considered to be good/very good in 70% of cases. Moreover, there was a reduction in levodopa dose in 20% of patients. Neurologists preferred levodopa/DDCI and entacapone compared with increasing levodopa dosage, dose-fractionation or addition of a dopamine agonist (63%, 29% and 23% of patients respectively). Reasons included achieving more continuous dopaminergic stimulation (40%), reducing motor fluctuations (54%) and improving ADL (41%). This analysis reveals the preference of neurologists for levodopa/DDCI and entacapone over conventional levodopa-modification strategies for the effective treatment of PD motor fluctuations in clinical practice.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002589 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002589 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:FB1AF7A778E8460826C64B435617CFBBC987FCD1 |texte= Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |